Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017, 36(36):5098-5109. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u2e2lEPTB;MD6wNFAxPTF|IN88US=> NF3wT4lUSU6JRWK=
NCI-H1703 NGXhfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHsenJZUUN3ME2wMlAxODlyMjFOwG0> MlzrV2FPT0WU
KASUMI-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HwUGlEPTB;MD6wNFY5OiEQvF2= MVHTRW5ITVJ?
CGTH-W-1 M2XuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEC3NlIh|ryP MVfTRW5ITVJ?
A204 NI\1XJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;kTmlEPTB;MD6wNFk6OiEQvF2= M3L0bnNCVkeHUh?=
HOP-62 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj4cmxKSzVyPUCuNVA5OzZizszN M2HDRnNCVkeHUh?=
H-EMC-SS MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2[YxKSzVyPUCuNVExODVizszN NFroXW9USU6JRWK=
KU812 M{Tkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojUTWM2OD1yLkG2OVc4KM7:TR?= NXXVPJFrW0GQR1XS
EM-2 M{HjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXM[2xKSzVyPUCuNVY5OTZizszN NWXlR4RsW0GQR1XS
LAMA-84 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml61TWM2OD1yLkG3OlY2KM7:TR?= MYjTRW5ITVJ?
JAR MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\XeXhKSzVyPUCuNlM6QDlizszN MkSxV2FPT0WU
G-361 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuwTWM2OD1yLkOyN|I2KM7:TR?= MWfTRW5ITVJ?
KG-1 M3nzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvemlEPTB;MD6zO|Y1OiEQvF2= MUXTRW5ITVJ?
BV-173 NGqxUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37PV2lEPTB;MD6zPVMzKM7:TR?= NXrJRodpW0GQR1XS
K5 M4PjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H4R2lEPTB;MD60NlEzPyEQvF2= Mm[2V2FPT0WU
MEG-01 NGL1R4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXETJlFUUN3ME2wMlQzOzZzIN88US=> MmKwV2FPT0WU
MFM-223 NHLGUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT1SWZJUUN3ME2wMlQ1Pzd4IN88US=> M{fH[3NCVkeHUh?=
BE-13 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn33TWM2OD1yLkWxNFA5KM7:TR?= NI\MPY1USU6JRWK=
NEC8 NWnNdo44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmixTWM2OD1yLkeyNVE{KM7:TR?= M1vJRnNCVkeHUh?=
SW756 NXracZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPnOYk2UUN3ME2wMlk6QDR4IN88US=> MULTRW5ITVJ?
A2780 NGT3ZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37DSmlEPTB;MT6wNVE1PiEQvF2= NGeyPHNUSU6JRWK=
NB14 NXXIb|E4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD1zLkCxPFAyKM7:TR?= MkjRV2FPT0WU
H4 NVux[IVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG1TWM2OD1zLkC2OFIzKM7:TR?= NXXYdJNOW0GQR1XS
SK-OV-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jn[mlEPTB;MT6wOlY{OyEQvF2= NHv3bJNUSU6JRWK=
AN3-CA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3OWYdKSzVyPUGuNFg{QDlizszN NVLSN|JzW0GQR1XS
A427 NFzpfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMUCzPFEh|ryP MYLTRW5ITVJ?
ES7 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6SmxKSzVyPUGuNVE{OzRizszN M3jhNnNCVkeHUh?=
AGS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLneo8yUUN3ME2xMlEyOzl3IN88US=> MV3TRW5ITVJ?
G-402 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfLWpdKSzVyPUGuNVQ3QTRizszN MV\TRW5ITVJ?
ES5 NWriNoppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrFTWM2OD1zLkG3NlQ5KM7:TR?= M4fKRXNCVkeHUh?=
DEL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37YeWlEPTB;MT6yOVQ2PyEQvF2= M1fVOHNCVkeHUh?=
NB10 NGjjXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwM{K1OVch|ryP MojhV2FPT0WU
NCI-H1581 NXTHOIZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P6OWlEPTB;MT6zPVA1OiEQvF2= NUW4bJVYW0GQR1XS
D-566MG M2\lPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGizPFZKSzVyPUGuOFA3QDNizszN NF7ENVVUSU6JRWK=
LXF-289 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmntTWM2OD1zLkSzPVk3KM7:TR?= M13Md3NCVkeHUh?=
BT-549 M1zNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwNU[5NFkh|ryP MVrTRW5ITVJ?
NKM-1 NXnzdGlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNkC1OVYh|ryP MWfTRW5ITVJ?
SW780 M3:5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNkWxOVgh|ryP NViwfoFOW0GQR1XS
NCI-H292 M3XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjpW4hrUUN3ME2xMlY3Ozh|IN88US=> NWfHepREW0GQR1XS
HMV-II M{H2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwN{C0PFgh|ryP MonLV2FPT0WU
ALL-PO NHrTNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjRfI9kUUN3ME2xMlgxODF3IN88US=> MljsV2FPT0WU
UACC-257 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PJNWlEPTB;MT64NlE3OyEQvF2= M1KwdXNCVkeHUh?=
PA-1 M1H1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1cWJTUUN3ME2xMlgzPzJ3IN88US=> MWLTRW5ITVJ?
HD-MY-Z Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;2TWM2OD1zLki2NlgyKM7:TR?= NHG1TGdUSU6JRWK=
HSC-4 M1W1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f6SmlEPTB;MT65N|g{QSEQvF2= NXfHVIFqW0GQR1XS
GCT NFjwU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvoTWM2OD1{LkCwPVE3KM7:TR?= MoDPV2FPT0WU
RT-112 NITjd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfLSpNGUUN3ME2yMlE{PDJ2IN88US=> MlLZV2FPT0WU
A172 NETNSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmP6TWM2OD1{LkGzOlA3KM7:TR?= MmSyV2FPT0WU
HCE-T NFX2V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjHdZZKSzVyPUKuNlA2QThizszN Mkn1V2FPT0WU
YH-13 M1rCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTmTWM2OD1{LkKxOlcyKM7:TR?= M4G0N3NCVkeHUh?=
DK-MG M3;PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xze2lEPTB;Mj6yN|g{PCEQvF2= M{Hud3NCVkeHUh?=
ACN Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMkO4O|Uh|ryP NUP4b2lSW0GQR1XS
VA-ES-BJ NX7FNnY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPoTWM2OD1{LkK0PVU4KM7:TR?= NV2xUYw6W0GQR1XS
L-363 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;PTWM2OD1{LkK4NFYyKM7:TR?= M4e2[3NCVkeHUh?=
HuH-7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVna[Zk6UUN3ME2yMlQzOTZ3IN88US=> M13UbHNCVkeHUh?=
A4-Fuk MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwNEexOlgh|ryP MnS4V2FPT0WU
T-24 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3LVGdKSzVyPUKuOFgxOzdizszN MmXmV2FPT0WU
GOTO Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGwSXlKSzVyPUKuOVMxOTNizszN M1TzT3NCVkeHUh?=
MV-4-11 NYflbnpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDYTlVKSzVyPUKuOVkyPjlizszN MULTRW5ITVJ?
DMS-114 MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJwNk[zOFUh|ryP MnG4V2FPT0WU
MHH-NB-11 M3PRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DabmlEPTB;Mj63NFI6QSEQvF2= M2HTeXNCVkeHUh?=
CHP-212 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nHPGlEPTB;Mj64NlA6OSEQvF2= NFTG[4ZUSU6JRWK=
DMS-273 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jcWlEPTB;Mj65NFIxPyEQvF2= M{[1b3NCVkeHUh?=
SF295 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTNwMEK1PVch|ryP Mo\1V2FPT0WU
NCI-H1563 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTwWJZKSzVyPUOuNVUxODVizszN MUjTRW5ITVJ?
NCI-H446 Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3XWlEPTB;Mz6yNlgxPSEQvF2= NIPGR3lUSU6JRWK=
HCC1806 NW\MWFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HGN2lEPTB;Mz6yO|Y2PyEQvF2= MUXTRW5ITVJ?
SF126 NV7qR5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW1PId5UUN3ME2zMlMxODF5IN88US=> MXvTRW5ITVJ?
SW982 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPIb2tKSzVyPUOuN|M5PzVizszN M4LIS3NCVkeHUh?=
ES8 M4nO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTNwM{S5PVkh|ryP Mnr6V2FPT0WU
SCC-4 M1zrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\wO3lKSzVyPUOuOVA{QTZizszN NV3Yepp[W0GQR1XS
RPMI-8226 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTNwNkK2NVYh|ryP MnXoV2FPT0WU
EW-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oc45bUUN3ME2zMlY{ODJ{IN88US=> MXXTRW5ITVJ?
COR-L105 NYDXUmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfnUGRKSzVyPUOuOlM{OzRizszN NGLybYZUSU6JRWK=
ES1 M3XEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNwOEOwPVQh|ryP M4X3[HNCVkeHUh?=
KMOE-2 NYPVNVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7WT|htUUN3ME2zMlkyQDB6IN88US=> M3fVd3NCVkeHUh?=
ABC-1 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHLN|BKSzVyPUOuPVM6OTFizszN MkW2V2FPT0WU
NCI-H526 NHm1PFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r2S2lEPTB;Mz65PVEzPiEQvF2= MUTTRW5ITVJ?
HCC1395 NUHLUo9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\PTWM2OD1|Lkm5OFg1KM7:TR?= MXjTRW5ITVJ?
DU-145 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P1bWlEPTB;ND6xNlgzPSEQvF2= M{XUZnNCVkeHUh?=
JEG-3 NWL3U4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPVTWM2OD12LkG1PVE3KM7:TR?= MVrTRW5ITVJ?
HCC1187 NV76VZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7QWHFKSzVyPUSuNlE2QTdizszN NHzzT3lUSU6JRWK=
LC-2-ad NXHVNlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T5emlEPTB;ND6yNlE4PyEQvF2= NXjlOpo3W0GQR1XS
ONS-76 M{S4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HIcWlEPTB;ND6yOFE6OiEQvF2= NILmXVZUSU6JRWK=
CAL-27 NYXYPIY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK3TWM2OD12LkK0N|Q1KM7:TR?= NHfWVGtUSU6JRWK=
8-MG-BA M33SPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:w[ohlUUN3ME20MlI3PjV6IN88US=> NXHSc5ZYW0GQR1XS
HGC-27 NXm3[YZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrZc2NlUUN3ME20MlI6PjZizszN NUK1[otMW0GQR1XS
Hs-578-T NWHN[mYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LwT2lEPTB;ND6zNVQ3QCEQvF2= NVvHTFFGW0GQR1XS
EW-1 M{Lwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PxN2lEPTB;ND61N|AyPCEQvF2= NFf6OpdUSU6JRWK=
SW1573 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XPUGlEPTB;ND61OVE3OyEQvF2= Mn\nV2FPT0WU
SNU-423 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DOSGlEPTB;ND62NFc6KM7:TR?= NXnaTYxjW0GQR1XS
HOS MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOwWJA3UUN3ME20MlY6PzdizszN NILze5FUSU6JRWK=
LB1047-RCC NInldG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP4fYZKSzVyPUSuPFE1OThizszN MnLrV2FPT0WU
ChaGo-K-1 NEX4XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTRwOEmwOFgh|ryP NY\5NVVsW0GQR1XS
A3-KAW NUixbGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLafHVKUUN3ME20Mlk4OzV{IN88US=> M1PwPXNCVkeHUh?=
CAS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLYTWM2OD12Lkm5PVA5KM7:TR?= NEeyeZFUSU6JRWK=
NBsusSR NHj2XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTVwMEO1NVQh|ryP M33penNCVkeHUh?=
KM12 NH3zfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXh[4lZUUN3ME21MlI6QDJ5IN88US=> NXvySWo5W0GQR1XS
NCI-H1155 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTGTWM2OD13LkO4NVg2KM7:TR?= MmPwV2FPT0WU
EFM-19 M{Tzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTVwNEG3N|ch|ryP M4WwRXNCVkeHUh?=
D-392MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPkfpVPUUN3ME21MlU4QDR7IN88US=> MUDTRW5ITVJ?
JVM-3 NXrCSVB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu2dI1KSzVyPUWuO|I{OjVizszN MofFV2FPT0WU
EW-16 NFrDZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVwN{W1PFMh|ryP M4rhWnNCVkeHUh?=
KARPAS-45 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1eWlEPTB;NT64OFMzPSEQvF2= NFXO[|lUSU6JRWK=
NCI-H28 NX3JPZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG5TWM2OD13Lki3PVE5KM7:TR?= MnLiV2FPT0WU
COLO-829 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFKyd5VKSzVyPUWuPVE2ODRizszN NWDFR5BwW0GQR1XS
KM-H2 NVGxXIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7hbmRzUUN3ME21MlkzOzl3IN88US=> NH:0T49USU6JRWK=
NCI-H82 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwOUK3O|Eh|ryP MnHyV2FPT0WU
OAW-42 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjzNG9KSzVyPUWuPVg5OjFizszN NGTTdWhUSU6JRWK=
A704 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTZTWM2OD14LkGwOVc1KM7:TR?= NWjSOJpwW0GQR1XS
NCI-H1048 NH63XGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjPGRMUUN3ME22MlExPTl7IN88US=> M4DyZnNCVkeHUh?=
LOXIMVI Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPWb3ZUUUN3ME22MlEyOjR6IN88US=> NEf3PY9USU6JRWK=
MKN45 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzZOm1wUUN3ME22MlI3ODF4IN88US=> NVPPeI97W0GQR1XS
D-502MG NI\YOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLXTWM2OD14LkK4PFU4KM7:TR?= MVXTRW5ITVJ?
HUTU-80 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X2VGlEPTB;Nj60NVY5QCEQvF2= MljFV2FPT0WU
S-117 NHXWZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\MVIZHUUN3ME22MlUxOjZ5IN88US=> NVzQTmhNW0GQR1XS
HCC1569 M{DQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rTR2lEPTB;Nj61N|c{PyEQvF2= NGfkPGRUSU6JRWK=
J-RT3-T3-5 NVToWJpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHLTWM2OD14LkW0OVczKM7:TR?= NW\5NHJlW0GQR1XS
OC-314 NVficpQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTZwOUGxOVkh|ryP MnjkV2FPT0WU
SNU-449 NHTFb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXvTJVKSzVyPUeuNFExPzJizszN NIfoPYhUSU6JRWK=
NCI-H720 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjqZmhFUUN3ME23MlE6OzR3IN88US=> NWf0Z3BwW0GQR1XS
KP-N-YS NFznS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS3TWM2OD15LkKwO|Ih|ryP M2KxcHNCVkeHUh?=
IGROV-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\2b21KSzVyPUeuN|I{QDZizszN MnW1V2FPT0WU
SK-PN-DW NEPWOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vZcmlEPTB;Nz60PFE2KM7:TR?= MUfTRW5ITVJ?
HCC1419 NGTkdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3GTWM2OD15LkWzJO69VQ>? NV\teZFDW0GQR1XS
HAL-01 NVe4[pBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu5NpFJUUN3ME23MlYxPjR2IN88US=> NX;1WnlMW0GQR1XS
HCC2998 M4XJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\JbmlEPTB;Nz62NFc1OyEQvF2= NYHINHJ1W0GQR1XS
SK-N-FI M4TuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\JTWM2OD15Lk[zNFM{KM7:TR?= M1nvXXNCVkeHUh?=
GI-ME-N MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzEZWU1UUN3ME23MlY1QTN2IN88US=> MYrTRW5ITVJ?
SW1088 NX\i[5ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe3XJFEUUN3ME23MlY2QDJ4IN88US=> M4XNSXNCVkeHUh?=
IA-LM MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLqdmU4UUN3ME23MlY5PjF|IN88US=> Mo\rV2FPT0WU
SK-NEP-1 NX\oeHlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\n[WJuUUN3ME23MlY6PjFizszN NF7aUVBUSU6JRWK=
MDA-MB-415 NW\1Ood[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTdwOEmxPFYh|ryP NXj1b5RbW0GQR1XS
COLO-800 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PaTGlEPTB;Nz65OFQ6OiEQvF2= M4Lz[XNCVkeHUh?=
NCI-H2228 M2\y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;DTWM2OD16LkG1O|g{KM7:TR?= NXO0coM5W0GQR1XS
D-423MG NIHj[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRThwMkG3NkDPxE1? M2PBZ3NCVkeHUh?=
TE-1 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRThwNESzNVYh|ryP NHnae|RUSU6JRWK=
NOS-1 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzWSpVyUUN3ME24MlUyPTN2IN88US=> NUTGeZRpW0GQR1XS
8505C M4e0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHZS3gyUUN3ME24MlY1QDJ2IN88US=> MnfMV2FPT0WU
HEC-1 NITOXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqzXXhKSzVyPUiuO|g1OzlizszN MUnTRW5ITVJ?
TE-11 NFXFXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzkTWM2OD16Lkm5OVUyKM7:TR?= NV\4SVJ7W0GQR1XS
CTB-1 NGTmVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvPTWM2OD17LkCxOFM{KM7:TR?= NHL4cZVUSU6JRWK=
TGBC11TKB NVrYfJRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTlwMEKyOFEh|ryP MXfTRW5ITVJ?
NB17 NX7aPJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v6UWlEPTB;OT6xPFg4KM7:TR?= M3fDfHNCVkeHUh?=
Becker MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnpS5k4UUN3ME25MlQyQTR2IN88US=> MoXTV2FPT0WU
SN12C NVjRNI5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPHeYZKSzVyPUmuOFUzOzRizszN MWDTRW5ITVJ?
COLO-320-HSR MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTlwNkCyN|ch|ryP NEj1R5RUSU6JRWK=
D-283MED MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXrRYNKSzVyPUmuOlMxPzJizszN MVXTRW5ITVJ?
D-263MG MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm2foJKSzVyPUmuPFM{QDRizszN MmPKV2FPT0WU
MEL-JUSO NIqwblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTxTHVKSzVyPUmuPVAyOjdizszN NFrxT4FUSU6JRWK=
T98G MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6TmdKSzVyPUmuPVAzODNizszN NVT2NYoyW0GQR1XS
HLE NIXlcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTlwOUC5NFkh|ryP MVnTRW5ITVJ?
Ca9-22 NGPBVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFyLkC2OlUh|ryP MknWV2FPT0WU
OS-RC-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizdpdKSzVyPUGwMlExPDVizszN Mm\XV2FPT0WU
T47D M3KxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFyLkG1OUDPxE1? M1jBNXNCVkeHUh?=
GI-1 NGjFT|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XWUGlEPTB;MUCuN|U{OyEQvF2= MnnZV2FPT0WU
NUGC-3 NEXmeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFyLkS0NFIh|ryP NHjENZNUSU6JRWK=
MDA-MB-361 NFq0c|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7WTWM2OD1zMD60OFMzKM7:TR?= NFz1XZRUSU6JRWK=
SCC-15 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyLkS3NVgh|ryP Mn;hV2FPT0WU
KS-1 NVjsVHNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFyLk[zNFEh|ryP Mnn5V2FPT0WU
CAL-12T MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFyLk[zOlEh|ryP NELXVnRUSU6JRWK=
OVCAR-4 MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFyLkewOlgh|ryP NIXEb5pUSU6JRWK=
HuP-T4 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzuWWRKSzVyPUGxMlA{OjhizszN M33OOnNCVkeHUh?=
NCI-H358 NYnZ[ZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPYc41yUUN3ME2xNU4zPjV5IN88US=> M{LGWHNCVkeHUh?=
HO-1-N-1 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTFzLkOzPVgh|ryP Ml\TV2FPT0WU
NH-12 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFzLkWzO|gh|ryP MnHLV2FPT0WU
MOLT-4 NEXkUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFzLkW5PFUh|ryP NVzK[IFxW0GQR1XS
K-562 NXrVS45ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTFzLkeyOFgh|ryP MUPTRW5ITVJ?
ES6 NYLObpV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnmXm9KSzVyPUGxMlg2QDFizszN NHjMSYhUSU6JRWK=
RO82-W-1 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTuPFE2UUN3ME2xNU46ODZ2IN88US=> M1\aVnNCVkeHUh?=
Ramos-2G6-4C10 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ReJdpUUN3ME2xNU46OzJizszN NVrN[IduW0GQR1XS
23132-87 NFnXfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDITWM2OD1zMj6wPFIyKM7:TR?= M{HoW3NCVkeHUh?=
A549 NGDQVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfnTWM2OD1zMj6zNlg2KM7:TR?= MVvTRW5ITVJ?
NCI-H23 NGr3PFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHyR5ZSUUN3ME2xNk42ODJ4IN88US=> MkDPV2FPT0WU
H9 NHvXfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF{LkW1O|ch|ryP MkTKV2FPT0WU
LB771-HNC NILFbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELBUolKSzVyPUGyMlc3PSEQvF2= M3f5RXNCVkeHUh?=
QIMR-WIL NUHze4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVeydJJGUUN3ME2xNk45OjV6IN88US=> MoriV2FPT0WU
HSC-3 NWn1TYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF{LkmyO|Yh|ryP NIDpfY1USU6JRWK=
PFSK-1 M2SyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS5fGJKSzVyPUGyMlk2ODdizszN NYr3XIVDW0GQR1XS
ETK-1 NHT5[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rzWmlEPTB;MUOuNFc4QSEQvF2= NI\VWmNUSU6JRWK=
SW1710 NY\sOIpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF|LkO2OFEh|ryP NX;teGhRW0GQR1XS
COLO-684 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7QVoFKSzVyPUGzMlQ2PDFizszN MmDMV2FPT0WU
RPMI-7951 NHvqdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXkOHdKSzVyPUGzMlUyOzZizszN NIHTXGJUSU6JRWK=
A101D Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTF|LkWzOFkh|ryP NHvxVFdUSU6JRWK=
KE-37 M2rnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF|LkW4PFch|ryP MX7TRW5ITVJ?
SiHa M1z3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nZcGlEPTB;MUOuPFM1PiEQvF2= NFTvS4pUSU6JRWK=
NCI-H226 M3n3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fOXmlEPTB;MUOuPFgxQCEQvF2= NXO4bod2W0GQR1XS
DB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\UeGtKSzVyPUGzMlk6OjhizszN NUTTbYREW0GQR1XS
HT-1197 M1X3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTWcWhKSzVyPUG0MlA5ODlizszN NEjZUG9USU6JRWK=
SBC-5 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KeI1YUUN3ME2xOE4yOzZ{IN88US=> MVXTRW5ITVJ?
VMRC-RCZ M3XDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LTR2lEPTB;MUSuOVc4PCEQvF2= M3rTfXNCVkeHUh?=
697 NYnEU5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF2Lk[yO{DPxE1? MXLTRW5ITVJ?
OMC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHntUIhKSzVyPUG0Mlc5QDhizszN MU\TRW5ITVJ?
SKG-IIIa NYrSeY92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\jOWlEPTB;MUSuPFAxOSEQvF2= MlP0V2FPT0WU
DOK NXjuTHl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTYTWM2OD1zND65PVM{KM7:TR?= MormV2FPT0WU
NCI-H2029 NFfpd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LIfmlEPTB;MUWuN|YxOiEQvF2= NGDsdlhUSU6JRWK=
NCI-H2009 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0cGlEPTB;MUWuOVA6PSEQvF2= NWfvV4hEW0GQR1XS
LK-2 NUfCcWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX3WoFEUUN3ME2xOU43PDR7IN88US=> M1L6c3NCVkeHUh?=
NCI-H661 NH25WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NESy[nZKSzVyPUG1MlkxPzVizszN M1TZUnNCVkeHUh?=
GT3TKB NYLtTlE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF4LkC2O|Yh|ryP M4mxTXNCVkeHUh?=
GP5d MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFna[IxKSzVyPUG2MlM1OiEQvF2= MV7TRW5ITVJ?
SK-MEL-2 NHTmZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF4LkS0PFUh|ryP M{SyTnNCVkeHUh?=
SK-UT-1 NH7qW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF4LkW2OUDPxE1? MmPTV2FPT0WU
NB7 NXz2N|A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\CTWM2OD1zNj62PVcyKM7:TR?= MnvNV2FPT0WU
NCI-H460 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1zNj63N|I3KM7:TR?= NWLQcohWW0GQR1XS
8305C MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HmZ2lEPTB;MU[uO|g4PyEQvF2= NYnNe|ZmW0GQR1XS
CaR-1 NYfvOHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF4LkixNVEh|ryP MX;TRW5ITVJ?
D-247MG MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF4Lki2NlUh|ryP MVvTRW5ITVJ?
LoVo MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K0OGlEPTB;MU[uPVQ5QCEQvF2= MkD1V2FPT0WU
NCI-H2405 M{LKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXqZo1KSzVyPUG3MlE6ODhizszN MlXJV2FPT0WU
AU565 NEXoRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\DTWM2OD1zNz6yNlUh|ryP M2fBfXNCVkeHUh?=
OCI-AML2 NUC1RXpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDLcXpKSzVyPUG3MlU{OTdizszN MXPTRW5ITVJ?
22RV1 NX;GWHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXJTWM2OD1zNz61PFg1KM7:TR?= NXryc|k6W0GQR1XS
HT-144 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXxSW5KSzVyPUG3MlY2QThizszN NGPZNGdUSU6JRWK=
HuO9 M4W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LVb2lEPTB;MUeuO|A{OSEQvF2= M1TYVHNCVkeHUh?=
Daoy NWLjWFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fOcWlEPTB;MUeuO|E5PCEQvF2= M1e3eHNCVkeHUh?=
SJRH30 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:zXWlEPTB;MUeuPFQ5QSEQvF2= Mn3YV2FPT0WU
CHL-1 NWPLdXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF5LkmyOFkh|ryP M1TMcXNCVkeHUh?=
J82 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXEdXBKSzVyPUG3Mlk3OzVizszN MUTTRW5ITVJ?
COR-L23 NUW3WHB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3LTWM2OD1zOD6wNFEyKM7:TR?= MWXTRW5ITVJ?
SNU-C2B MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fCTGlEPTB;MUiuNlI4PiEQvF2= MX3TRW5ITVJ?
NCI-H1770 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHWSGFPUUN3ME2xPE41PjF3IN88US=> M{PVWHNCVkeHUh?=
MHH-PREB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PiT2lEPTB;MUiuOVY6PyEQvF2= MYjTRW5ITVJ?
ES3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF6LkW4PFMh|ryP M2HRcnNCVkeHUh?=
MDA-MB-231 NXuyfYtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF6Lk[1NFIh|ryP NVHkVXRWW0GQR1XS
MN-60 NVPvRolbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHMTWM2OD1zOT6wOVkzKM7:TR?= M3rIT3NCVkeHUh?=
EPLC-272H NXjM[2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPS[phVUUN3ME2xPU4{PzB6IN88US=> NED3UZJUSU6JRWK=
SW948 M1Pod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\3TWM2OD1zOT6zPVM1KM7:TR?= NIq2[nZUSU6JRWK=
MOLT-13 NXiyZ3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnMTWM2OD1zOT60OVQ3KM7:TR?= NWPFZnJKW0GQR1XS
HL-60 MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XqRWlEPTB;MkCuNlE1OSEQvF2= MlXrV2FPT0WU
CP50-MEL-B M1fke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XVV2lEPTB;MkCuOFc1QCEQvF2= MkTOV2FPT0WU
NTERA-S-cl-D1 M4XaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJyLkS5O|gh|ryP MYfTRW5ITVJ?
KINGS-1 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu0RoZKSzVyPUKwMlc6PjdizszN MU\TRW5ITVJ?
DOHH-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHDTWM2OD1{MD65NFYh|ryP M3\OeXNCVkeHUh?=
BB65-RCC M4TOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PLPWlEPTB;MkCuPVI5PSEQvF2= NU\SVYFtW0GQR1XS
NB12 NHPsd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHiRnJKSzVyPUKxMlA{QTRizszN MXHTRW5ITVJ?
KY821 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Dkd2lEPTB;MkGuOVgzKM7:TR?= M2LUV3NCVkeHUh?=
PSN1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1SWlEPTB;MkGuOlQ2OyEQvF2= NGrNVo5USU6JRWK=
EGI-1 M1KzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljBTWM2OD1{MT63OFU1KM7:TR?= M{jJOnNCVkeHUh?=
CTV-1 NYOwUYVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2raXmlEPTB;MkKuN|A{OSEQvF2= NIfydZBUSU6JRWK=
TI-73 NXf2UWROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\4NmlEPTB;MkKuN|Q6QCEQvF2= NHK4UmVUSU6JRWK=
LCLC-103H MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ{LkS3OVIh|ryP NILyWodUSU6JRWK=
D-542MG NGDGZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ{LkW1OVgh|ryP NFPXcVVUSU6JRWK=
ATN-1 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK3UZFKSzVyPUKyMlY1OzlizszN M2Pt[nNCVkeHUh?=
SK-MEL-1 NXy4eo14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ{LkizOlgh|ryP NVzPUHBpW0GQR1XS
HDLM-2 NF\DbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf5PGpKSzVyPUKzMlE1PzhizszN MXvTRW5ITVJ?
UM-UC-3 NWnqRnlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XDVGlEPTB;MkOuNVk1PCEQvF2= M1HVNXNCVkeHUh?=
NCI-H1573 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ|LkS2PFEh|ryP MkPtV2FPT0WU
NCI-H520 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfITWM2OD1{Mz60PVQ5KM7:TR?= NGDkVWtUSU6JRWK=
ESS-1 M3vIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TxOmlEPTB;MkOuPFA2QSEQvF2= NWjOUJlUW0GQR1XS
COR-L88 NXvlXnU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3DeVdEUUN3ME2yN{46PDd3IN88US=> MkT0V2FPT0WU
TGBC24TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf1eYF3UUN3ME2yOE4xOzF{IN88US=> MkTyV2FPT0WU
HCC1937 NXjqNok5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHvfXRKSzVyPUK0MlEh|ryP NEe3N3hUSU6JRWK=
RS4-11 M1PY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPZ[IdXUUN3ME2yOE4yPDJizszN M2XFNHNCVkeHUh?=
HCC38 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ2LkKzPVQh|ryP M1\NOnNCVkeHUh?=
RPMI-2650 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLmcFdTUUN3ME2yOE43OTZ{IN88US=> NXPiWVZZW0GQR1XS
P12-ICHIKAWA NH\CZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vTUGlEPTB;MkSuOlI2QCEQvF2= NXfZWmN{W0GQR1XS
YAPC M4L5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPkV|FiUUN3ME2yOE45OjF2IN88US=> NYLE[ZdsW0GQR1XS
NB13 M3K3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3sWYxKSzVyPUK1MlI3OTFizszN NYTBNZFIW0GQR1XS
SK-N-AS NYjvZlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPDTWM2OD1{NT64OVg1KM7:TR?= MYDTRW5ITVJ?
SK-N-DZ NGG3VJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoezTWM2OD1{Nj6wOFkh|ryP MoLBV2FPT0WU
LS-411N M13EOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjHXIZKSzVyPUK2MlIxOzhizszN NF7W[FBUSU6JRWK=
NCI-H810 NI\LS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj5TXpyUUN3ME2yOk4{OTF{IN88US=> NXjyUmo5W0GQR1XS
NCI-SNU-1 NYfTVZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi0dVhKSzVyPUK2MlU1PTRizszN NHTvNIxUSU6JRWK=
HH MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXWTWM2OD1{Nj61OVI6KM7:TR?= NVLQcI1VW0GQR1XS
U-2-OS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ4LkezPFIh|ryP NUHNOGpDW0GQR1XS
SF539 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;PTWM2OD1{Nj64NFE5KM7:TR?= NULrUZdrW0GQR1XS
NCI-H2052 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r3emlEPTB;MkeuNFg3KM7:TR?= MX7TRW5ITVJ?
A673 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ5LkKxNFIh|ryP MWHTRW5ITVJ?
WM-115 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ5Lke3Olch|ryP NIjMTplUSU6JRWK=
SW48 NWPzN3k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvDPZlKSzVyPUK3MlgxODVizszN NU\Bb3ZEW0GQR1XS
NOMO-1 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHWTWM2OD1{Nz64OVMzKM7:TR?= NVXaWZpnW0GQR1XS
PC-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ5Lki5OFEh|ryP M3uzbXNCVkeHUh?=
UMC-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ5LkmzOFMh|ryP NWq4SlFjW0GQR1XS
U-118-MG MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ6LkCxNlMh|ryP M3XiPXNCVkeHUh?=
NCI-H2452 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLEVYNKSzVyPUK4MlA5OjJizszN NETGT2pUSU6JRWK=
CAMA-1 M3y3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ6Lki1OlQh|ryP MWrTRW5ITVJ?
MC-IXC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nNN2lEPTB;MkmuNlM3PiEQvF2= NXrKXGs6W0GQR1XS
ES4 NGDYRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV35eXlbUUN3ME2yPU4{OTd{IN88US=> MmPoV2FPT0WU
BHT-101 M4PsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[5dXdKSzVyPUK5MlMzOSEQvF2= MYXTRW5ITVJ?
KP-4 NYPPOG9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHFdGdKSzVyPUK5MlUyPiEQvF2= MXPTRW5ITVJ?
CAL-54 NE\IWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYiy[pNpUUN3ME2yPU42PDR3IN88US=> MVPTRW5ITVJ?
5637 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ7Lk[0NlEh|ryP MYfTRW5ITVJ?
MOLT-16 NUnBdFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLQfVlKUUN3ME2yPU44OjZ7IN88US=> MkWyV2FPT0WU
Ca-Ski MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ7Lkm0OkDPxE1? MWTTRW5ITVJ?
AsPC-1 M37kdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNyLkCyNVIh|ryP NEfLTYZUSU6JRWK=
MSTO-211H NGjyOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rpWWlEPTB;M{CuNVUh|ryP M{HhVHNCVkeHUh?=
L-428 NFXvUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKzfFlKSzVyPUOwMlQxPSEQvF2= MlTrV2FPT0WU
SW1463 NYHjNYpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTY[W9KSzVyPUOwMlU{QDNizszN NXLWSI9qW0GQR1XS
NCI-H1648 NEO2[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\5cI9KSzVyPUOwMlU2PzRizszN NILhXJBUSU6JRWK=
CAKI-1 NUjUNoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNyLke3NFIh|ryP MmXUV2FPT0WU
YKG-1 NEXhSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNzLkCyOlMh|ryP NUPFR3B4W0GQR1XS
A2058 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNzLkGxOlQh|ryP MYnTRW5ITVJ?
A375 M2D6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:xTWM2OD1|MT6xOlk3KM7:TR?= MmLuV2FPT0WU
SNB75 NXrBU3M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K2cWlEPTB;M{GuNlQ{PSEQvF2= M{T0ZXNCVkeHUh?=
SK-HEP-1 NEnwbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\VV2lEPTB;M{GuOFI4OSEQvF2= M1zuNHNCVkeHUh?=
ME-180 NWC0SphUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPqW2pKSzVyPUOxMlY2PDJizszN NX7xXXY{W0GQR1XS
NCI-H209 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTFZZZKSzVyPUOxMlgzPDdizszN MnP5V2FPT0WU
HC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnRUIRbUUN3ME2zNk4yPDR4IN88US=> MkfaV2FPT0WU
LB373-MEL-D NFnPUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfWTWM2OD1|Mj6xPVcyKM7:TR?= M{DienNCVkeHUh?=
SNU-387 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLwNWY{UUN3ME2zNk4{OTlzIN88US=> MoPPV2FPT0WU
C32 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN{LkOzOVMh|ryP MX;TRW5ITVJ?
EW-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvGRnVKSzVyPUOyMlk1ODhizszN M2fVPXNCVkeHUh?=
BFTC-905 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDIdWJUUUN3ME2zN{42OTN4IN88US=> Mn3WV2FPT0WU
NCI-H1299 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ETWM2OD1|Mz61OlIyKM7:TR?= M3jrS3NCVkeHUh?=
LU-135 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojTTWM2OD1|Mz64NFEh|ryP M3i5dXNCVkeHUh?=
NCI-H2122 NHr6VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTN|Lkm5OlYh|ryP M1e2RnNCVkeHUh?=
SK-LMS-1 MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnznTWM2OD1|ND60NVA4KM7:TR?= MnXnV2FPT0WU
LNCaP-Clone-FGC NVrYNVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vqcGlEPTB;M{SuPFUyPSEQvF2= MY\TRW5ITVJ?
NCI-H1092 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnJTWM2OD1|NT6yO|Q4KM7:TR?= M2PHS3NCVkeHUh?=
MS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi3TWM2OD1|NT6zNFM5KM7:TR?= MknrV2FPT0WU
KYSE-510 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr0TWM2OD1|NT61NFQzKM7:TR?= NUP6UIFoW0GQR1XS
NCI-H1793 M1PzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTN3Lk[1OFUh|ryP MWrTRW5ITVJ?
MIA-PaCa-2 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfsTWM2OD1|Nj6wOFk3KM7:TR?= MlP1V2FPT0WU
EW-22 NVu4XIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\qfFhLUUN3ME2zOk41ODd{IN88US=> M36zSHNCVkeHUh?=
IGR-1 M3fuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn70TWM2OD1|Nj64NVg1KM7:TR?= MkLKV2FPT0WU
HT-1080 NUPSV4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j5TWlEPTB;M{euNVI2KM7:TR?= MlrZV2FPT0WU
M14 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN5LkG2OFIh|ryP NITDNpdUSU6JRWK=
786-0 MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN5LkK3PVQh|ryP NUCyVHllW0GQR1XS
MZ2-MEL NV;TWGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrIeXVKSzVyPUO3MlQ2ODFizszN NHfub4xUSU6JRWK=
NCI-H510A Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLDTm1QUUN3ME2zO{46PDF{IN88US=> M3TOWHNCVkeHUh?=
LAN-6 NWfNeWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN5Lkm1PFIh|ryP M4LMfHNCVkeHUh?=
SW620 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfoV|JtUUN3ME2zPE41QTd2IN88US=> Ml3iV2FPT0WU
LB2241-RCC Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL6W45KSzVyPUO5MlgzODVizszN NHK2c5JUSU6JRWK=
Detroit562 NIL5[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL4c5JKSzVyPUSwMlEzPjhizszN M2XZS3NCVkeHUh?=
HN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTBUXVwUUN3ME20NE4yPzh{IN88US=> M4rjXHNCVkeHUh?=
HCT-15 NIW0Z2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTRyLkW5NFch|ryP MmTnV2FPT0WU
C2BBe1 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi0SlZKSzVyPUSwMlkyPTdizszN MkjvV2FPT0WU
A498 NFHWe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRzLkOwNVUh|ryP NFe5PWdUSU6JRWK=
SK-MEL-24 NXvDeIxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXzfXZKSzVyPUSxMlQ4OjVizszN NIK1fmxUSU6JRWK=
OVCAR-5 MmXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrGTWM2OD12MT63O|Y4KM7:TR?= NVHEV5l{W0GQR1XS
NCI-H1792 M2XEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\CTWM2OD12MT65PFIyKM7:TR?= MU\TRW5ITVJ?
KOSC-2 NF3FN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3YfHpKSzVyPUSyMlI3QTlizszN NY\OXHFMW0GQR1XS
Mo-T MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7qbldKSzVyPUSyMlg6PThizszN NEfsRVNUSU6JRWK=
CFPAC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP2bG9mUUN3ME20N{41QTR2IN88US=> NULld2dFW0GQR1XS
CAL-51 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPX[3RQUUN3ME20N{42PjB3IN88US=> NV3WNWxjW0GQR1XS
RH-18 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR|LkiwOUDPxE1? NH3yfXlUSU6JRWK=
EC-GI-10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTR|LkizOFch|ryP MkP0V2FPT0WU
HSC-2 NF72VW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TqUmlEPTB;NESuNFA6KM7:TR?= NYqyR3FMW0GQR1XS
ML-2 M3v4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvSUlFVUUN3ME20OU4zPjJzIN88US=> NXjx[Jl5W0GQR1XS
KNS-81-FD M2jVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTUNVZKSzVyPUS1Mlc{PjVizszN NYmxcYd{W0GQR1XS
NB6 M1GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC1TWM2OD12Nj6xNVEh|ryP NYTQc4ltW0GQR1XS
MCF7 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zEV2lEPTB;NE[uOVU{OyEQvF2= NGftc4tUSU6JRWK=
P30-OHK NFjGSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrlVlhKSzVyPUS2MlgyOTdizszN M4G1TXNCVkeHUh?=
BPH-1 M{TyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;1eJBsUUN3ME20Ok46QDB3IN88US=> MXjTRW5ITVJ?
U251 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjHVGNKSzVyPUS2Mlk6PCEQvF2= M{\tRnNCVkeHUh?=
MKN1 NUizTItHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zISWlEPTB;NEeuOVE{PyEQvF2= NVWwU4o1W0GQR1XS
A431 NI\SXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmVYxKSzVyPUS3Mlg{OzhizszN MmPxV2FPT0WU
C8166 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;WTWM2OD12OT6yNFM6KM7:TR?= NV;NO2F{W0GQR1XS
HEL MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTR7LkSwOlQh|ryP MY\TRW5ITVJ?
RMG-I NYjxRpczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvdIlvUUN3ME20PU41PDR2IN88US=> MoTEV2FPT0WU
CAL-72 NUHmcGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nmTmlEPTB;NEmuOlA4PSEQvF2= MmLrV2FPT0WU
SW962 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPFcmpOUUN3ME20PU46OzN{IN88US=> MV\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03595124 Recruiting Metastatic Renal Cell Carcinoma|Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|TFE3 Gene Translocation|TFEB Gene Translocation National Cancer Institute (NCI) October 9 2018 Phase 2
NCT03275558 Withdrawn Recurrent Glioblastoma|Gliosarcoma|Anaplastic Gliomas Center Trials & Treatment July 17 2018 Phase 1
NCT02156895 Recruiting Advanced Renal Cell Carcinoma Pfizer July 17 2018 --
NCT03472560 Recruiting Non-Small Cell Lung Cancer|Urothelial Cancer Pfizer May 2 2018 Phase 2
NCT03481842 Not yet recruiting Endometriosis|Endometriosis Ovary|Endometriosis Externa|Endometriosis Rectum BioGene Pharmaceutical Ltd.|Dr. Łanevska J. May 3 2018 Phase 1|Phase 2
NCT03438708 Recruiting Clear Cell Renal Cell Carcinoma University of California San Diego|The Cleveland Clinic March 5 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products4

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID